Circulating Omentin-1 Across BMI Categories in Type 2 Diabetes and its Association with Insulin Resistance: A Cross-Sectional Study from South India Authors: Saidaiah Ikkurthi, A. R. Srinivasan, Vaikkakara Suresh, Rajendran Jayanthi, Vidya S. Desai Published: 2026 ABSTRACT Introduction:Omentin-1 is an adipocytokine predominantly secreted by visceral adipose tissue and associated with insulin sensitivity. Altered levels of omentin-1 in type 2 diabetes mellitus (T2DM) and obesity denote a potential link with insulin resistance.Methods:Two hundred twenty-five adult males with T2DM were segregated into non-obese (n = 75), overweight (n = 75), and obese (n = 75) groups. Anthropometric, haemodynamic, and biochemical parameters, including glucose, insulin, lipid profile, and omentin-1 were measured. Insulin resistance was assessed using validated surrogate indices. Group comparisons were performed and associations were examined using correlation analysis and a prespecified multivariable linear regression model.Results:Obese subjects had higher BMI, waist-to-hip ratio, fasting glucose, HbA1c, fasting insulin, HOMA-IR, lipid fractions, and METS-IR as compared to non-obese. Serum omentin-1 levels declined progressively with increasing adiposity [non-obese 687.6 (654.1–763.2), overweight 587.6 (548.6–658.1), obese 459.3 (398.7–524.8) ng/L; P < 0.001]. Omentin-1 showed inverse correlations with BMI (γ = −0.703), waist-to-hip ratio (γ = −0.717), HOMA-IR (γ = −0.403), triglyceride-BMI index (γ = −0.695), and LDL-cholesterol (γ = −0.417), and a positive correlation with QUICKI (γ =0.403; all P < 0.001). In the multivariable model, LDL-cholesterol remained independently associated with circulating omentin-1 levels (β =2.527, P = 0.043).Conclusion:Serum omentin-1 shows an inverse association with adiposity, insulin resistance, and lipid parameters in T2DM, suggesting that omentin-1 could serve as a potential marker of an adverse cardiometabolic profile, although comprehensive studies are further warranted. INTRODUCTION Type 2 diabetes mellitus (T2DM) affects approximately 537 million individuals worldwide, with India alone accounting for nearly 74 million cases.[1] T2DM is characterised by impaired insulin action and resultant hyperglycaemia.[2] Metabolic dysregulation, adipose tissue dysfunction, and chronic low-grade inflammation are central to the pathogenesis of T2DM.[3] The adipokine omentin-1, also known as intelectin-1, has emerged as a candidate molecule for understanding the links between lipid metabolism and metabolic disorders[4] omentin-1 is predominantly expressed by visceral adipose tissue and has been implicated in metabolic homeostasis, inflammation, and insulin sensitivity.[5] The omentin-1 gene is located at the 1q22–q23 chromosomal locus, which has been associated with susceptibility to T2DM.[6] Among the two homologous isoforms, omentin-1 and omentin-2, omentin-1 represents the major circulating form.[7] Several studies have reported lower circulating omentin-1 levels in both type 1 and type 2 diabetes. Normal-weight individuals exhibit higher omentin-1 concentrations, which are inversely correlated with body mass index, waist circumference, leptin levels, and insulin resistance, and positively correlated with adiponectin and high-density lipoprotein cholesterol.[8] However, the pattern of circulating omentin-1 across different degrees of adiposity in individuals with T2DM and its association with insulin resistance indices remains incompletely characterised, particularly in the Indian population. This study therefore aimed to examine circulating omentin-1 levels across BMI-defined subgroups of adults with T2DM and to evaluate their associations with anthropometric, metabolic, and insulin resistance parameters. By exploring these associations, this study seeks to contribute to a better understanding of adipokine-related metabolic alterations in T2DM. MATERIALS AND METHODS Study population This cross-sectional study included 225 adult males with type 2 diabetes mellitus (T2DM) recruited between September 2020 and December 2023. Participants were categorised based on body mass index (BMI) as non-obese (18.5–22.9 kg/m²; n = 75), overweight (23.0–27.5 kg/m²; n = 75), and obese (>27.5 kg/m²; n = 75). The three groups were comparable in age (18–60 years). Individuals with known hepatic, renal, cardiovascular, thyroid, or neuromuscular disorders were excluded. Data on age, lifestyle factors, family history of diabetes, and medication use were collected using a structured questionnaire. Duration of diabetes mellitus was obtained from medical records and patient history, and all participants had a duration of less than 5 years, reflecting early-stage disease. Anthropometric measurements and calculation of indices Anthropometric assessment All participants underwent a standardised physical examination. Height was measured without footwear to the nearest 0.5 cm, and body weight was recorded to the nearest 0.1 kg using a calibrated electronic scale. Waist circumference was measured midway between the lower margin of the last palpable rib and the top of the iliac crest, and hip circumference was measured at the widest part of the gluteal region. Waist-to-hip ratio was calculated as waist circumference divided by hip circumference, and body mass index was calculated as weight (kg) divided by height squared (m²). Blood pressure was measured in the sitting position using an automated sphygmomanometer, and the mean of two readings taken five minutes apart was recorded. Sample collection Fasting venous blood samples were obtained after an overnight fast of 8–10 h. Samples were centrifuged to separate plasma and serum, aliquoted, and stored at − 80°C until analysis. Biochemical analysis Fasting plasma glucose, total cholesterol, triglycerides, and high-density lipoprotein cholesterol were measured using enzymatic methods on an automated analyser. Low-density lipoprotein cholesterol was calculated using the Friedewald formula, as none of the participants had triglyceride levels exceeding 400 mg/dL. Glycated haemoglobin (HbA1c) was estimated by high-performance liquid chromatography. Serum insulin and omentin-1 concentrations were measured using commercially available enzyme-linked immunosorbent assay kits according to the manufacturers’ instructions. Serum omentin-1 was measured using a sandwich ELISA kit (Human omentin-1 ELISA kit, Krishgen Biosystems, India). The assay has a detection range of approximately 10–1000 ng/L, with a lower limit of detection of ~5 ng/L. The intra-assay and inter-assay coefficients of variation were <8% and <10%, respectively. All samples were analysed in duplicate, and serum samples were stored at −80°C and subjected to no more than one freeze-thaw cycle prior to analysis. Insulin resistance indices The following indices were used: HOMA-IR = (Fasting insulin × Fasting glucose)/405[9] TyG index = Ln [Triglycerides × Glucose/2][10] TyG-BMI = TyG × BMI[11] Atherogenic Index of Plasma (AIP) = Log (Triglycerides/HDL-C)[12] METS-IR = Log [(2 × Glucose + Triglycerides × BMI)/(log HDL-C)][13] QUICKI = 1/[Log (Insulin) + Log (Glucose)][14] HOMA-β (%) =360 × Insulin/(Glucose – 63)[15] Statistical analysis Data are presented as median (interquartile range). Group comparisons were performed using the Kruskal–Wallis test with Bonferroni adjustment for multiple comparisons. Associations between variables were examined using Spearman’s rank correlation. A prespecified multivariable linear regression model was used to examine factors independently associated with circulating omentin-1 levels. Statistical significance was defined as a two-sided P value < 0.05. Ethical aspects The study was approved by the Institutional Ethics Committee, AIIMS Mangalagiri (Reference No: AIIMS/MG/IEC/2020-21/57, dated 19-09-2020). Written informed consent was obtained from all participants for study participation and use of data for research and educational purposes. The study procedures adhered to the Declaration of Helsinki (1964) and its later amendments. RESULTS Table 1 summarises the baseline anthropometric, physiological, and biochemical characteristics of participants with type 2 diabetes mellitus stratified by body mass index into non-obese, overweight, and obese groups. The three groups were comparable with respect to age (P = 0.349), while significant differences were observed across most anthropometric and metabolic variables (all P < 0.001). Table 1Baseline anthropometric, physiological, and biochemical characteristics of participants with type 2 diabetes mellitus stratified by BMIParameterNon-obese (n=75)Overweight (n=75)Obese (n=75) P Age (years)48 (43–57)50 (43–56)47 (42–53)0.349SBP (mmHg)126 (123–127)138 (131–140)148 (143–152)<0.001DBP (mmHg)84 (83–86)87 (84–89)91 (89–93)<0.001Mean arterial pressure (mmHg)98.3 (97–99.7)103.7 (101–105.7)109.3 (107–112.3)<0.001Weight (kg)69 (63–71)78 (74–82)90 (89–93)<0.001Height (m)1.75 (1.65–1.77)1.68 (1.61–1.73)1.61 (1.58–1.65)<0.001BMI (kg/m²)22.7 (21.8–23.3)27.3 (26.4–29.6)33.3 (33.0–36.6)<0.001Waist circumference (cm)84 (80–86)112 (110–116)124 (120–128)<0.001Hip circumference (cm)95 (92–96)98 (95–100)100 (98–102)<0.001Waist–hip ratio0.88 (0.87–0.90)1.14 (1.12–1.17)1.21 (1.20–1.24)<0.001Fasting blood sugar (mg/dL)138 (130–157)146 (132–168)167 (146–186)<0.001HbA1c (%)6.6 (6.2–7.5)7.2 (6.3–8.2)8.7 (7.4–10.4)<0.001Estimated average glucose (mg/dL)142.7 (131.2–168.6)159.9 (134.1–188.6)203 (165.7–251.8)<0.001Fasting plasma insulin (mIU/L)17.1 (15.2–18.7)21.2 (19.9–23.4)23.3 (20.1–26.6)<0.001HOMA-IR5.86 (5.19–6.70)7.8 (7.1–8.9)9.61 (7.46–11.7)<0.001QUICKI0.30 (0.29–0.30)0.286 (0.281–0.289)0.279 (0.272–0.287)<0.001HOMA-β (%)80.7 (65.4–92.6)91.3 (69.8–112.3)82.5 (63.3–109.3)0.028Total cholesterol (mg/dL)222 (201–266)249 (225–269)290 (272–301)<0.001Triglycerides (mg/dL)165 (146–179)172 (156–220)206 (187–246)<0.001TyG index4.04 (4.01–4.14)4.14 (4.07–4.21)4.24 (4.14–4.35)<0.001TyG-BMI91.8 (88.5–96.6)113.3 (108.9–121.8)146.9 (139.8–157.2)<0.001HDL-C (mg/dL)33 (31–36)31 (29–32)29 (26–31)0.004LDL-C (mg/dL)156 (139.8–192)181.4 (152.8–204)218 (195.8–233.6)<0.001VLDL-C (mg/dL)33 (29.2–35.8)34.2 (31–44)41.2 (37.4–49.2)<0.001AIP0.69 (0.63–0.76)0.75 (0.68–0.86)0.86 (0.79–0.95)<0.001Body fat % (BMI method)22.2 (19.9–24.8)28.4 (26–31.1)36.6 (33.9–39)<0.001METS-IR39.6 (37.4–41.8)49.83 (47.8–53.7)65.2 (61.9–68.9)<0.001Omentin-1 (ng/L)687.6 (654.1–763.2)587.6 (548.6–658.1)459.3 (398.7–524.8)<0.001 Baseline anthropometric, physiological, and biochemical characteristics of participants with type 2 diabetes mellitus stratified by BMI Obese participants had higher blood pressure, body weight, waist and hip circumferences, waist–hip ratio, and body fat percentage compared with non-obese and overweight participants. Fasting plasma glucose, HbA1c, fasting insulin, HOMA-IR, triglycerides, total cholesterol, LDL-cholesterol, VLDL-cholesterol, triglyceride-BMI index, atherogenic index of plasma, and METS-IR increased progressively with adiposity (all P < 0.001), whereas HDL-cholesterol and QUICKI decreased. HOMA-β (%) was highest in the overweight group (P = 0.028), suggesting a relative compensatory β-cell response. Circulating omentin-1 levels declined across BMI categories—non-obese [687.6 (654.1–763.2)], overweight [587.6 (548.6–658.1)], and obese [459.3 (398.7–524.8) ng/L] (P < 0.001)—and showed inverse associations with BMI and other indices of adiposity. Data are presented as median (interquartile range).T2DM: type 2 diabetes mellitus; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure; BMI: body mass index; WHR: waist–hip ratio; HOMA-IR: homeostasis model assessment of insulin resistance; HOMA-β: homeostasis model assessment of β-cell function; HbA1c: glycated haemoglobin; eAG: estimated average glucose; FPI: fasting plasma insulin; QUICKI: quantitative insulin sensitivity check index; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; VLDL-C: very low-density lipoprotein cholesterol; TyG: triglyceride-glucose index; TG-BMI: triglyceride-body mass index; AIP: atherogenic index of plasma; METS-IR: metabolic score for insulin resistance. Table 2 presents the post hoc pairwise comparisons with Bonferroni adjustment following the Kruskal–Wallis test. Significant differences were observed across most anthropometric and metabolic variables among the BMI-defined T2DM groups. Obese participants had higher systolic and diastolic blood pressure, mean arterial pressure, body weight, body mass index, waist and hip circumferences, and waist–hip ratio compared with both overweight and non-obese participants (all P < 0.001). Overweight participants also differed significantly from non-obese participants, reflecting a graded increase in adiposity indices. Table 2Pairwise comparisons with Bonferroni adjustment following the Kruskal–Wallis testParameterNon-obese vs overweightNon-obese vs obeseOverweight vs obeseSBP (mmHg)<0.001<0.001<0.001DBP (mmHg)0.001<0.001<0.001MAP (mmHg)<0.001<0.001<0.001Weight (kg)<0.001<0.001<0.001Height (m)<0.001<0.0010.001BMI (kg/m²)<0.001<0.001<0.001Waist circumference (cm)<0.001<0.001<0.001Hip circumference (cm)<0.001<0.0010.004Waist–hip ratio<0.001<0.001<0.001Fasting blood sugar (mg/dL)0.189<0.0010.016HbA1c (%)0.014<0.001<0.001Estimated average glucose (mg/dL)0.014<0.001<0.001Fasting plasma insulin (mIU/L)<0.001<0.0010.363HOMA-IR<0.001<0.0010.033QUICKI0.033<0.001<0.001HOMA-β (%)0.5930.0230.501Total cholesterol (mg/dL)0.158<0.001<0.001Triglycerides (mg/dL)0.034<0.001<0.001TyG index0.001<0.001<0.001TyG-BMI<0.001<0.001<0.001HDL-C (mg/dL)0.013<0.001<0.001LDL-C (mg/dL)0.16<0.001<0.001VLDL-C (mg/dL)0.047<0.001<0.001AIP0.001<0.001<0.001Body fat %<0.001<0.001<0.001METS-IR<0.001<0.001<0.001Omentin-1 (ng/L)<0.001<0.001<0.001 Pairwise comparisons with Bonferroni adjustment following the Kruskal–Wallis test Glycaemic variables, including HbA1c, estimated average glucose, fasting insulin, and HOMA-IR, increased progressively with adiposity (all P < 0.001), whereas QUICKI decreased across all intergroup comparisons (P < 0.05). HOMA-β was lower in obese compared with non-obese participants (P = 0.023), indicating reduced β-cell function. Lipid parameters, including triglycerides, LDL-cholesterol, VLDL-cholesterol, and total cholesterol, increased and HDL-cholesterol decreased with higher BMI (all P < 0.001). Derived indices (TyG, TyG-BMI, AIP, and METS-IR) also increased significantly across BMI categories (all P < 0.001). Circulating omentin-1 levels were significantly lower across all pairwise comparisons (all P < 0.001), showing inverse associations with adiposity and metabolic indices in T2DM. Table 3 shows the bivariate correlation analysis between circulating omentin-1 and anthropometric and metabolic parameters in the T2DM cohort. omentin-1 showed significant inverse correlations with body mass index (γ = −0.703), waist–hip ratio (γ = −0.717), systolic blood pressure (γ = −0.703), fasting insulin (γ = −0.430), HOMA-IR `−0.403), triglycerides (γ = −0.361), TyG-BMI index (γ = −0.695), atherogenic index of plasma (γ = −0.441), and METS-IR (γ = −0.695) (all P < 0.001). In contrast, omentin-1 correlated positively with QUICKI (γ = 0.403) and HDL-cholesterol (γ = 0.354) (both P < 0.001). Table 3Bivariate correlations and multivariable regression analysis of factors associated with circulating omentin-1VariableCorrelation (r) P Regression (β) P Lower CIUpper CIAge (years)0.1010.1320.600.385−0.7581.956SBP (mmHg)−0.703<0.001−2.270.085−4.8560.315DBP (mmHg)−0.542<0.001−3.260.103−7.1960.669Mean arterial pressure (mmHg)−0.694<0.0010.660.429−0.9812.299Weight (kg)−0.706<0.0011.560.781−9.51512.640Height (m)0.442<0.001−461.520.371−1476.6553.633BMI (kg/m²)−0.703<0.00158.560.400−78.414195.540Waist circumference (cm)−0.656<0.001−10.460.709−65.80944.881Hip circumference (cm)−0.381<0.0019.980.518−20.45640.408Waist–hip ratio−0.717<0.001321.990.809−2308.72952.686Fasting plasma glucose (mg/dL)−0.154<0.0012.4970.503−4.8419.835Estimated average glucose (mg/dL)−0.279<0.0010.1090.489−0.2010.418Fasting plasma insulin (mIU/L)−0.430<0.0017.7620.733−37.00652.530HOMA-IR−0.403<0.001−23.1100.458−84.39738.176QUICKI0.403<0.001−5078.1490.459−18592.78436.417HOMA-β (%)−0.1160.084−1.1780.490−4.5432.186Triglycerides (mg/dL)−0.361<0.001−0.7600.801−6.6985.177TyG index−0.695<0.001−804.8720.620−4001.532391.794TyG-BMI−0.695<0.001−17.8490.259−48.96913.270HDL-C (mg/dL)0.354<0.0018.4280.616−24.68041.536LDL-C (mg/dL)−0.417<0.0012.5270.0430.0824.972VLDL-C (mg/dL)−0.366<0.001−1.3720.918−27.55024.807AIP−0.441<0.0011361.3780.390−1755.894478.651METS-IR−0.695<0.0010.0030.998−2.4562.463 Bivariate correlations and multivariable regression analysis of factors associated with circulating omentin-1 In the prespecified multivariable linear regression model, LDL-cholesterol remained independently associated with circulating omentin-1 levels (β = 2.527, P = 0.043; 95% CI: 0.082–4.972). Other variables that were significant in bivariate analysis were not retained in the multivariable model, likely reflecting collinearity among adiposity- and lipid-related indices. Overall, circulating omentin-1 levels were lower in individuals with greater adiposity, insulin resistance, and dyslipidaemia. The distribution of concomitant medications across BMI groups is presented in Table 4. Table 4Distribution of concomitant medications across BMI groupsMedicationNon-obese (n=75)Overweight (n=75)Obese (n=75)Metformin60 (80.0%)65 (86.7%)70 (93.3%)Sulfonylurea18 (24.0%)15 (20.0%)12 (16.0%)DPP-4 inhibitor19 (25.3%)16 (21.3%)15 (20.0%)SGLT2 inhibitor12 (16.0%)19 (25.3%)31 (41.3%)GLP-1 receptor agonist5 (6.7%)13 (17.3%)21 (28.0%)Statin45 (60.0%)50 (66.7%)56 (74.7%)Insulin0 (0%)0 (0%)0 (0%)Values are expressed as number (percentage) of subjects in each group. Subjects receiving exogenous insulin were excluded by study design Distribution of concomitant medications across BMI groups Values are expressed as number (percentage) of subjects in each group. Subjects receiving exogenous insulin were excluded by study design DISCUSSION Circulating omentin-1 levels declined progressively across non-obese, overweight, and obese groups of individuals with type 2 diabetes mellitus, in parallel with increasing adiposity, insulin resistance, and dyslipidaemia. These findings extend previous observations and suggest that lower omentin-1 levels are associated with adverse metabolic profiles in T2DM. As expected, obese participants exhibited higher body mass index, waist–hip ratio, fasting insulin, HOMA-IR, TyG, and METS-IR, together with lower HDL-cholesterol and QUICKI, consistent with impaired insulin sensitivity and cardiometabolic risk.[161718] The observed inverse associations between omentin-1 and anthropometric indices, insulin resistance markers, and atherogenic lipid parameters, as well as the positive associations with QUICKI and HDL-cholesterol, are in agreement with prior studies from Asian and European populations.[19202122] These consistent patterns across diverse cohorts support a robust relationship between omentin-1 and metabolic health, although the cross-sectional nature of the present study precludes causal inference. In the multivariable model, LDL-cholesterol remained independently associated with circulating omentin-1 levels; however, this finding should be interpreted cautiously given potential treatment effects and collinearity with other lipid and adiposity indices. This finding suggests a link between omentin-1 and lipid metabolism, potentially reflecting shared regulation by hepatic lipid handling, adipose tissue function, or inflammatory pathways. Importantly, most lipid- and glucose-lowering therapies used in this cohort would be expected to lower LDL-cholesterol or improve insulin sensitivity, and therefore any treatment-related effects would likely attenuate, rather than exaggerate, the observed associations.[2324] The cross-sectional design does not permit causal inference. The absence of a non-diabetic control group limits comparisons to within type 2 diabetes across adiposity strata. Although medication use was recorded and broadly similar across groups, residual confounding cannot be completely excluded. Inflammatory markers and direct measures of visceral fat or lean mass were not available. Overall, the present study provides novel data from a South Indian population demonstrating consistent associations between circulating omentin-1, adiposity, insulin resistance, and dyslipidaemia in T2DM. These findings suggest that omentin-1 may serve as a potential marker of adverse cardiometabolic profile, warranting further investigation in longitudinal and interventional studies to clarify its prognostic and clinical relevance. CONCLUSION Circulating omentin-1 levels showed significant inverse associations with adiposity, insulin resistance, and dyslipidaemia in individuals with type 2 diabetes mellitus. The independent association between omentin-1 and LDL-cholesterol suggests a relationship with lipid metabolism and cardiometabolic risk. These findings support the need for further longitudinal and mechanistic studies to clarify the prognostic and clinical utility of omentin-1 in diabetes management. Author contributions Concept and design: Saidaiah Ikkurthi, A.R. Srinivasan. Data acquisition and analysis: Saidaiah Ikkurthi, V. Suresh. Interpretation of data: Saidaiah Ikkurthi, R. Jayanthi, Vidya Sripad Desai. Drafting and revising the manuscript: Saidaiah Ikkurthi, A.R. Srinivasan. All authors reviewed and approved the final version. Conflicts of interest There are no conflicts of interest. Use of artificial intelligence Artificial intelligence tools (ChatGPT, OpenAI, Version GPT-5, used in October 2025) were employed only for English language editing and formatting assistance. The authors take full responsibility for the integrity and scientific accuracy of the manuscript content. Data availability statement The data supporting the findings of this study are available from the corresponding author upon request.